Integrin beta-3 genetic variants and risk of venous thromboembolism in colorectal cancer patients

scientific article published on 28 August 2015

Integrin beta-3 genetic variants and risk of venous thromboembolism in colorectal cancer patients is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1016/J.THROMRES.2015.08.010
P698PubMed publication ID26440977

P50authorAngelika GeroldingerQ64007617
Cihan AyQ66126625
Heinz-Josef LenzQ89668545
Gabriela KornekQ110415456
P2093author name stringIngrid Pabinger
Alexandra Kaider
Christoph C Zielinski
Alexandra Schuler
Werner Scheithauer
Gerald W Prager
Clemens Pausz
Daniela Bianconi
P2860cites workCoagulation and cancer: biological and clinical aspectsQ38070918
Insights in microRNAs biologyQ38112762
Biomarkers for prediction of venous thromboembolism in cancerQ38125998
Risk factors for venous thromboembolism in cancer: novel findings from the Vienna Cancer and Thrombosis Study (CATS).Q38214965
Integrin beta 3 expression is regulated by let-7a miRNA in malignant melanoma.Q39954054
Soluble Vascular Endothelial Growth Factor (sVEGF) and the Risk of Venous Thromboembolism in Patients with Cancer: Results from the Vienna Cancer and Thrombosis Study (CATS).Q41456560
Integrin genetic variants and stage-specific tumor recurrence in patients with stage II and III colon cancerQ41714515
CD98hc (SLC3A2) interaction with the integrin beta subunit cytoplasmic domain mediates adhesive signaling.Q46066210
Prediction of venous thromboembolism in cancer patients.Q51662626
A solution to the problem of monotone likelihood in Cox regression.Q52929496
High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS).Q53472586
Association of mean platelet volume with risk of venous thromboembolism and mortality in patients with cancer. Results from the Vienna Cancer and Thrombosis Study (CATS).Q54489258
A note on quantifying follow-up in studies of failure timeQ71721709
Venous thrombosis in patients with solid tumors: determination of frequency and characteristicsQ74090799
Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapyQ79825413
Incidence of venous thromboembolism and its effect on survival among patients with common cancersQ82676244
Venous thromboembolism in patients with colorectal cancer: incidence and effect on survivalQ82676944
Thrombosis risk and survival in cancer patients with elevated C-reactive proteinQ85100868
Tumor grade is associated with venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis StudyQ87372024
An integrated map of genetic variation from 1,092 human genomesQ22122153
Kindlin-1 and -2 directly bind the C-terminal region of beta integrin cytoplasmic tails and exert integrin-specific activation effectsQ24657848
Risk of venous thromboembolism in patients with cancer: a systematic review and meta-analysisQ27005043
Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trialQ28185738
Kindlin-2 controls bidirectional signaling of integrinsQ28507652
A note on including time-dependent covariate in regression model for competing risks dataQ31031448
Platelet membrane defects in Glanzmann's thrombasthenia. Evidence for decreased amounts of two major glycoproteinsQ33483955
The final steps of integrin activation: the end gameQ34106011
Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice GuidelinesQ34215315
Function and interactions of integrinsQ34381197
Genetic variation of ITGB3 is associated with asthma in Chinese Han childrenQ34602730
Signaling during platelet adhesion and activationQ34895427
Integrin targeted therapeuticsQ34912684
MicroRNA function: multiple mechanisms for a tiny RNA?Q36325449
American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer.Q36984787
Antithrombotic effects of targeting alphaIIbbeta3 signaling in plateletsQ37157980
Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysisQ37328873
Roles of integrins in tumor angiogenesis and lymphangiogenesis.Q37354204
Cancer, clots and consensus: new understanding of an old problem.Q37393386
Assessing risk of venous thromboembolism in the patient with cancer.Q37393394
Venous thromboembolism risk in patients with cancer receiving chemotherapy: a real-world analysisQ37404403
The role of β3-integrins in tumor angiogenesis: context is everythingQ37874786
Angiogenesis in cancer. Basic mechanisms and therapeutic advancesQ37916313
Endothelial progenitor cells and integrins: adhesive needsQ37992761
RGD-based strategies to target alpha(v) beta(3) integrin in cancer therapy and diagnosisQ38042484
Risk of venous thromboembolism in patients with cancer treated with Cisplatin: a systematic review and meta-analysis.Q38059698
Cancer-associated thrombosis: updates and controversiesQ38066930
P433issue5
P921main subjectcolorectal cancerQ188874
venous thromboembolismQ9397786
colorectal carcinomaQ25493920
P304page(s)865-869
P577publication date2015-08-28
P1433published inThrombosis ResearchQ15758741
P1476titleIntegrin beta-3 genetic variants and risk of venous thromboembolism in colorectal cancer patients
P478volume136

Reverse relations

cites work (P2860)
Q57824763Cancer-associated thrombosis: The search for the holy grail continues
Q88979484Common rs5918 (PlA1/A2) polymorphism in the ITGB3 gene and risk of coronary artery disease
Q55297156Expression and role of VEGFA and miR-381 in portal vein tumor thrombi in patients with hepatocellular carcinoma.
Q98183400Genes and proteins associated with the risk for cancer-associated thrombosis
Q28066805Integrins in the Spotlight of Cancer
Q98778926Roles of microRNA-186 and vascular endothelial growth factor in hepatocellular carcinoma complicated with portal vein tumor thrombus
Q53142866Variant alleles in factor V, prothrombin, plasminogen activator inhibitor-1, methylenetetrahydrofolate reductase and risk of thromboembolism in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab.

Search more.